

Review I01 BX002367 from the US Department of Veterans Affairs (to J.M.W.).

The contents do not represent the views of the US Department of Veterans Affairs or the US Government.

DISCLOSURES

None.

REFERENCES

1. Fine LG, Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney diseases: From hypothesis to novel therapeutics. *Kidney Int* 74: 867–872, 2008
2. Evans RG, Ow CP, Bie P: The chronic hypoxia hypothesis: The search for the smoking gun goes on. *Am J Physiol Renal Physiol* 308: F101–F102, 2015
3. Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK: Failed tubule recovery, AKI-CKD transition, and kidney disease progression. *J Am Soc Nephrol* 26: 1765–1776, 2015
4. Scandurra FM, Gnaiger E: Cell respiration under hypoxia: Facts and artefacts in mitochondrial oxygen kinetics. *Adv Exp Med Biol* 662: 7–25, 2010
5. Gnaiger E, Steinlechner-Maran R, Méndez G, Eberl T, Margreiter R: Control of mitochondrial and cellular respiration by oxygen. *J Bioenerg Biomembr* 27: 583–596, 1995
6. Abdelkader A, Ho J, Ow CP, Eppel GA, Rajapakse NW, Schlaich MP, Evans RG: Renal oxygenation in acute renal ischemia-reperfusion injury. *Am J Physiol Renal Physiol* 306: F1026–F1038, 2014
7. Rosenberger C, Rosen S, Paliege A, Heyman SN: Pimonidazole adduct immunohistochemistry in the rat kidney: Detection of tissue hypoxia. *Methods Mol Biol* 466: 161–174, 2009
8. Basile DP, Donohoe DL, Roethe K, Mattson DL: Chronic renal hypoxia after acute ischemic injury: Effects of L-arginine on hypoxia and secondary damage. *Am J Physiol Renal Physiol* 284: F338–F348, 2003
9. Goldfarb M, Rosenberger C, Abassi Z, Shina A, Zilbersat F, Eckardt KU, Rosen S, Heyman SN: Acute-on-chronic renal failure in the rat: Functional compensation and hypoxia tolerance. *Am J Nephrol* 26: 22–33, 2006
10. Tanaka S, Tanaka T, Nangaku M: Hypoxia as a key player in the AKI-to-CKD transition. *Am J Physiol Renal Physiol* 307: F1187–F1195, 2014
11. Jiang BH, Semenza GL, Bauer C, Marti HH: Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O₂ tension. *Am J Physiol* 271: C1172–C1180, 1996
12. Lin SL, Chang FC, Schrimpf C, Chen YT, Wu CF, Wu VC, Chiang WC, Kuhnert F, Kuo CJ, Chen YM, Wu KD, Tsai TJ, Duffield JS: Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. *Am J Pathol* 178: 911–923, 2011
13. Kramann R, Wongboonsin J, Chang-Panesso M, Machado FG, Humphreys BD: Gli1+ pericyte loss induces capillary rarefaction and proximal tubular injury. *J Am Soc Nephrol* 28: 776–784, 2017
14. Kida Y, Ieronimakis N, Schrimpf C, Reyes M, Duffield JS: EphrinB2 reverse signaling protects against capillary rarefaction and fibrosis after kidney injury. *J Am Soc Nephrol* 24: 559–572, 2013
15. Kramann R, Schneider RK, DiRocco DP, Machado F, Fleig S, Bondzie PA, Henderson JM, Ebert BL, Humphreys BD: Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. *Cell Stem Cell* 16: 51–66, 2015

See related article, “Gli1+ Pericyte Loss Induces Capillary Rarefaction and Proximal Tubular Injury,” on pages 776–784.

HIV-1 Infection of Renal Cells in HIV-Associated Nephropathy

Leslie A. Bruggeman

Department of Medicine, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio

J Am Soc Nephrol 28: 719–721, 2017.

doi: 10.1681/ASN.2016111171

“If there is one thing the history of evolution has taught us it’s that life will not be contained. Life breaks free, it expands to new territories and crashes through barriers.” (Dr. Ian Malcolm in *Jurassic Park*)

Some of the deadliest infectious agents to humanity arose by host range expansion, jumping species barriers, whereas others engage in an evolutionary arms race with the human immune system to survive. Two of these, HIV-1 and trypanosomes, have converged to define the etiology of HIV-associated nephropathy (HIVAN), a rapidly progressive CKD that occurs in the setting of HIV-1 infection but only in individuals of recent African ancestry. Early in the United States HIV/AIDS epidemic and before effective antiretroviral treatment, approximately 10% of the HIV-seropositive black population developed HIVAN. At the same time in the epidemic, the HIV-seropositive white population did not develop HIVAN.

In the current paradigm, HIVAN is caused by direct HIV-1 infection of renal epithelial cells. This is made on the basis of several corroborating observations: viral nucleic acids are present in podocytes and tubular epithelial cells in human biopsies, HIVAN can be recapitulated in transgenic mouse models expressing the viral DNA in renal cells, and antiretroviral therapy has reduced the incidence of HIVAN and improved renal function and pathology in patients with HIVAN.¹ However, renal epithelial cells lack the receptor (CD4) and coreceptors (CCR5 or CXCR4) that are required for HIV-1 infection in T cells and macrophages, a conundrum that has left some in the HIV/AIDS research community skeptical that HIVAN results from direct renal cell infection. Fueling the controversy are the inconsistent and contradictory reports on whether cultured renal epithelial cells can be infected by HIV-1 *in vitro*, and whether the infection is productive (capable of producing new infectious virus) or abortive.²

Although the canonical CD4 receptor-mediated entry mechanism *via* interaction with the viral coat protein gp120 is highly efficient, additional (albeit less efficient) mechanisms of HIV infection have been described for other immune cell types and have

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Leslie Bruggeman, Rammelkamp Bldg. Room R429, MetroHealth Medical Center, 2500 MetroHealth, Cleveland, OH 44109. Email: leslie.bruggeman@case.edu

Copyright © 2017 by the American Society of Nephrology

been examined in renal cells.³ These alternative mechanisms include the use of other receptors, such as c-type lectins or cell surface heparan sulfate proteoglycans, which bind the heavily glycosylated gp120 by nonspecific electrostatic interactions, and the adherent virus is subsequently engulfed by endocytosis, phagocytosis, or pinocytosis. Within the cell, whether this engulfed virus can escape the endocytic vacuole and proceed through the viral lifecycle is unclear. The engulfed virus can be trafficked to lysosomes and degraded, or enter recycling endosomes and return to the extracellular environment unchanged, neither of which would result in a chronically infected cell or a productive infection. Cell-mediated mechanisms of infection have also been described that require a direct cell contact with an infected immune cell. Shed virus from the immune cell is confined and protected within the cell–cell junction composed of lipid raft microdomains (termed virologic synapse), which also supports endocytic uptake. Although the cell–cell transmission of virus has been documented *in vitro*, how this occurs *in vivo* is unclear, and it would be considerably more challenging for a functional virologic synapse to form in the complex tissue anatomy of the kidney.

In the report by Li *et al.*,⁴ a new piece to the kidney infection puzzle has been added: the role of inflammation to prime renal cells for infection. Using a clever unbiased screening method, Li *et al.* identified membrane bound TNF (tm-TNF) as a host protein that facilitated more efficient *in vitro* infection of cell-free virus entering by a dynamin-dependent endocytic mechanism. TNF expression is inducible in most renal cells, is initially synthesized as a transmembrane protein, and soluble TNF (sTNF) can be produced by ectodomain shedding. The functions of sTNF in the inflammatory response are well described; however, the functional roles of tm-TNF are not well understood but may involve novel outside-in or inside-out signaling events related to its roles as both a ligand and a receptor.⁵ Some of these signaling events, including robust NF- κ B activation, are well known to enhance viral replication. However, Li *et al.* determined NF- κ B activation was not the tm-TNF-dependent event that enhanced infection in podocytes. Infection could be blocked with either the addition of a TNF neutralizing antibody or expression of an inactive TNF mutant, but activation of NF- κ B by sTNF treatment did not recreate the enhanced infectivity initiated by tm-TNF expression. Although the actual mechanism of entry through tm-TNF was not defined in this study, on the basis of the methods used, the results suggest some aspect of tm-TNF trimerization, integration or organization into lipid rafts, or potentially oligomerization with other receptors may be important events in the enhanced viral entry.

Another well established concept in the HIVAN paradigm is that HIVAN occurs only in populations of recent African ancestry worldwide. This includes current sub-Saharan African populations where HIVAN is a significant complication of HIV

infection. In the United States, Blacks and Dominican, Cuban, and Puerto Rican Hispanics, who trace ancestry to these same African populations, are similarly susceptible to HIVAN and are at greater risk for other forms of CKD.⁶ The recent identification of polymorphisms in *APOL1* that are common in black ancestry but absent in white ancestry explains this genetic susceptibility.¹ *APOL1* is a unique molecule in the primate innate immune armamentarium with efficient trypanosome killing activity. Polymorphisms in *APOL1* arose and were selected for in recent African populations to restore killing activity against a *Trypanosoma brucei* subspecies that itself evolved as a counter-mechanism to evade wild-type *APOL1* killing. Individuals homozygous for these *APOL1* polymorphisms (referred to as risk alleles), for reasons yet to be established, have a substantially increased risk for HIVAN in the setting of uncontrolled HIV-1 infection with a 29-fold higher odds ratio compared with whites.⁷ Approximately 12%–15% of the United States black population are homozygous for *APOL1* risk alleles, and this percentage closely matches the prevalence of HIVAN (10%) in the HIV-infected United States black population early in the epidemic. Recent studies, however, have discounted the role of the abundant *APOL1* plasma protein as causing kidney disease,^{8,9} and thus attention is now focused on the role of *APOL1* protein expressed in kidney cells as the key player in the *APOL1*-dependent pathogenic mechanism.^{10,11}

Interestingly, Li *et al.* did examine HIV-1 infection in podocyte cell lines that were either homozygous for wild-type *APOL1* (G0/G0) or homozygous for *APOL1* risk alleles (G1/G1). No difference was found in the infection of these cell lines. Considering the converging evidence of both HIV-1 infection and *APOL1* expression in podocytes as fundamental events in HIVAN pathogenesis, it seems logical there must be a functional interaction between *APOL1* and some aspect of the HIV-1 lifecycle that is different with the *APOL1* risk alleles. Identifying this intracellular connection is our best opportunity to define the intracellular role of *APOL1* in podocytes, which may explain the genetic predisposition not only to HIVAN but also other kidney diseases associated with *APOL1* risk alleles. Two recent studies have identified a role for wild-type *APOL1* in suppressing HIV-1 replication.^{12,13} These studies suggest *APOL1* is a new host restriction factor for HIV-1 (and possibly other viruses) that could be exploited for future antiviral therapy development. Whether the *APOL1* risk alleles have lost these virus restriction functions has not been tested.

HIV-1 has found a way into renal cells, but the key question is why does this cause kidney disease only in the host with *APOL1* risk alleles? *APOL1* evolved as part of our immune system, and it is tempting to speculate *APOL1* may have an additional immune role against viruses. Understanding the HIVAN pathogenic mechanism remains incomplete until we understand the normal function of *APOL1* in the kidney and what is lost or gained with the *APOL1* risk alleles.

ACKNOWLEDGMENTS

L.A.B. is supported by National Institutes of Health grants DK095832, DK097836, and DK108329.

DISCLOSURES

None.

REFERENCES

- Rosenberg AZ, Naicker S, Winkler CA, Kopp JB: HIV-associated nephropathies: Epidemiology, pathology, mechanisms and treatment. *Nat Rev Nephrol* 11: 150–160, 2015
- Bruggeman LA, Nelson PJ: Controversies in the pathogenesis of HIV-associated renal diseases. *Nat Rev Nephrol* 5: 574–581, 2009
- Melikyan GB: HIV entry: A game of hide-and-fuse? *Curr Opin Virol* 4: 1–7, 2014
- Li J, Das JR, Tang P, Han Z, Jasiwal JK, Ray PE: Transmembrane TNF facilitates HIV-1 infection of podocytes cultured from children with HIV-associated nephropathy. *J Am Soc Nephrol* 28: 862–875, 2017
- Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T: Transmembrane TNF- α : Structure, function and interaction with anti-TNF agents. *Rheumatology (Oxford)* 49: 1215–1228, 2010
- Udler MS, Nadkarni GN, Belbin G, Lotay V, Wyatt C, Gottesman O, Bottinger EP, Kenny EE, Peter I: Effect of Genetic African Ancestry on eGFR and kidney disease. *J Am Soc Nephrol* 26: 1682–1692, 2015
- Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA: APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. *J Am Soc Nephrol* 22: 2129–2137, 2011
- Bruggeman LA, O'Toole JF, Ross MD, Madhavan SM, Smurzynski M, Wu K, Bosch RJ, Gupta S, Pollak MR, Sedor JR, Kalayjian RC: Plasma apolipoprotein L1 levels do not correlate with CKD. *J Am Soc Nephrol* 25: 634–644, 2014
- Kozlitina J, Zhou H, Brown PN, Rohm RJ, Pan Y, Ayanoglu G, Du X, Rimmer E, Reilly DF, Roddy TP, Cully DF, Vogt TF, Blom D, Hoek M: Plasma levels of risk-variant APOL1 do not associate with renal disease in a population-based cohort. *J Am Soc Nephrol* 27: 3204–3219, 2016
- Ma L, Shelness GS, Snipes JA, Murea M, Antinozzi PA, Cheng D, Saleem MA, Satchell SC, Banas B, Mathieson PW, Kretzler M, Hemal AK, Rudel LL, Petrovic S, Weckerle A, Pollak MR, Ross MD, Parks JS, Freedman BI: Localization of APOL1 protein and mRNA in the human kidney: Nondiseased tissue, primary cells, and immortalized cell lines. *J Am Soc Nephrol* 26: 339–348, 2015
- Madhavan SM, O'Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR: APOL1 localization in normal kidney and nondiabetic kidney disease. *J Am Soc Nephrol* 22: 2119–2128, 2011
- Taylor HE, Khatua AK, Popik W: The innate immune factor apolipoprotein L1 restricts HIV-1 infection. *J Virol* 88: 592–603, 2014
- McLaren PJ, Gawanbacht A, Pyndiah N, Krapp C, Hotter D, Kluge SF, Götz N, Heilmann J, Mack K, Sauter D, Thompson D, Perreaud J, Rausell A, Munoz M, Ciuffi A, Kirchhoff F, Telenti A: Identification of potential HIV restriction factors by combining evolutionary genomic signatures with functional analyses. *Retrovirology* 12: 41, 2015

See related article, "Transmembrane TNF- α Facilitates HIV-1 Infection of Podocytes Cultured from Children with HIV-Associated Nephropathy," on pages 862–875.

Should Transplant Referral Be a Clinical Performance Measure?

Ashwini R. Sehgal*[†]

*Division of Nephrology and [†]Center for Reducing Health Disparities, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio

J Am Soc Nephrol 28: 721–723, 2017.
doi: 10.1681/ASN.2016111169

ESRD providers and policymakers have long been at the forefront of efforts to improve health care quality. The Medicare program currently monitors dialysis facility performance related to vascular access, dialysis dose, mineral metabolism, anemia management, bloodstream infections, patient satisfaction, hospitalization, and mortality.¹ By contrast, access to kidney transplantation is not a routine part of Medicare quality improvement efforts. This may be because transplantation is viewed as beyond the purview of dialysis facilities. In addition, the severe shortage of organs for transplantation may raise questions about the ultimate effect of any quality improvement initiatives.

However, many of the barriers to receiving a kidney transplant occur while patients with ESRD are being cared for by dialysis facilities. Obtaining a transplant requires patients to successfully complete a series of six sequential steps: (1) medical suitability (*i.e.*, no absolute contraindications to transplantation); (2) interest in considering a deceased or living donor transplant; (3) referral to transplant center initiated by the patient, nephrologist, or other dialysis facility staff; (4) transplant center workup, including medical history, physical examination, psychosocial assessment, evaluation and treatment of medical conditions, and laboratory studies; (5) placement on deceased donor waiting list or identification of potential living donor; and (6) transplant from deceased or living donor. Most patients on dialysis are unable to complete the first three steps, which occur before transplant providers are involved.²

In this issue of the *Journal of the American Society of Nephrology*, Patzer *et al.*³ show that interventions directed at dialysis facility practices can improve transplant referral, a task that reflects successful completion of the first three steps in the kidney transplant process. The authors randomly assigned 134 Georgia facilities to a control group that received usual care or an intervention group that received transplant education and engagement activities that targeted dialysis facility leadership, staff, and patients. After 1 year, intervention facilities referred 7.3% more patients to transplant centers. The benefit of the

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Ashwini R. Sehgal, 2500 MetroHealth Drive, Cleveland, OH 44109. Email: sehgal@case.edu

Copyright © 2017 by the American Society of Nephrology